<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00406380</url>
  </required_header>
  <id_info>
    <org_study_id>APEC-0024</org_study_id>
    <nct_id>NCT00406380</nct_id>
  </id_info>
  <brief_title>Effect of Avastin in Juxtafoveal Telangiectasias</brief_title>
  <official_title>Does Avastin Change Evolution in Juxtafoveal Telangiectasias?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación para Evitar la Ceguera en México</source>
  <brief_summary>
    <textblock>
      Evaluation of efficacy of Intravitreal Injection of Bevacizumab in patients with Yuxtafoveal
      Telangiectasias
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After diagnose Yuxtafoveal telangiectasias secondary to Branch Retinal Vein Occlusion and
      with Idiopathic Ethiology by clinical signs and Fluorescein angiogram (FA)findings we treated
      patients with Intravitreal Injection of Bevacizumab (2.5mg/0.1ml). We performed a complete
      ophthalmological evaluation and at baseline and follow-up (1 and 3 months) we evaluate ETDRS
      Best Corrected visual acuity (BCVA), fluorescein angiogram (FA) and Optical Coherence
      Tomography (OCT)findings. We found an improvement in visual acuity and reduction of FA
      leakage and decrease retinal thickness in OCT.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2006</start_date>
  <completion_date>November 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected Visual Acuity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Fluorescein Angiogram: Leakage</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Optical Coherence Tomography: Retinal thickness</measure>
  </primary_outcome>
  <condition>Telangiectasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intravitreal injection of Bevacizumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Telangiectasias secondary to Branch Retinal Vein Occlusion

          -  Patients with Idiopathic Juxtafoveal Retinal Telangiectasias

        Exclusion Criteria:

          -  Diabetic Retinopathy and Diabetic Macular Edema

          -  Hypertensive Retinopathy

          -  Choroidal Neovascularization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Veronica Kon-Jara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asociación para Evitar la Ceguera en México</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Verónica Kon-Jara, MD</last_name>
    <phone>5510841400</phone>
    <phone_ext>1171-1172</phone_ext>
    <email>veronicakon@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Orlando Ustariz-Gonzalez, MD</last_name>
    <phone>5510841400</phone>
    <phone_ext>1171-1172</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asociacion para Evitar la Ceguera en Mexico</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Kon-Jara, MD</last_name>
      <phone>5510841400</phone>
      <phone_ext>1171-1172</phone_ext>
      <email>veronicakon@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Orlando Ustariz-Gonzalez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Reyna-Castelan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nelida Salazar-Teran, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jans Fromow-Guerra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hugo Quiroz-Mercado, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>November 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2006</study_first_submitted>
  <study_first_submitted_qc>December 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2006</study_first_posted>
  <last_update_submitted>December 1, 2006</last_update_submitted>
  <last_update_submitted_qc>December 1, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2006</last_update_posted>
  <keyword>Telangiectasias</keyword>
  <keyword>Leakage</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Telangiectasias secondary to Branch Retinal Vein Occlusion (BRVO)</keyword>
  <keyword>Idiopathic juxtafoveal retinal telangiectasias</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

